Collaborative Targets Sample Clauses

Collaborative Targets. Combined targets from the collaborative KMPF project (agreed by all partners) are to raise applications and subsequent conversions to higher education from within the 40 target schools and colleges in LPNs Number of Member Schools: 40 Increase Year group 2011-12 – Same as Xx0-0, Xx0-0, Xx0-0, Xxxxxxxx range of year participation Number and % of 2011-12 1116 1204 1292 targets groups who across years total student Yr9, 1116 Yr9, 1204 Yr9, have been participate in 7-13 in each exchanges 1292 set to outreach programmes school Yr 7-8, 631 Yr10, 2093 Yr11, 3627 Yr10, 2258 Yr10, 2423 reflect increased Yr 9, 657 Yr 10,2395 Yr12-13 5999 Yr11, 3913 Yr12-13 Yr11, 4199 number of schools from 29 to Yr 11, 3007 Total 6472 Yr12, 6945 40 and to increase Yr 12- 13, 5061 13951 Yr13, proportion Total 16151 of total Total - 11751 15051 exchanges delivered Total to younger 16151 year groups – Yr 7-9 KS4 Destination - – Increase proportion who stay on in education after KS5 Reduce the gap between KMPF schools and LA average % of KS5 entrants who stay on to any education destination in year following KS4 exam entry 2009-10 KMPF – 80% LA average – 85% Gap – 5% pts 2010-11 81% 2010- 11 2011-12 82% 2012-13 83% 2013 -14 84% DfE Destination Measures Create new base-line for 2014 cohort (data will be available in 2017) Improve KS4 results % of disadvantage students 5A*-C including achieving English and Maths 2011 21% average across KMPF schools a Kent LA average 29% b Medway LA average 25% 25% 30% 32% 34% 36% Take into account changing examinatio n practice and elimination of modular Measure gap between KMPF schools and LA average exams – monitor reduction in gap between KMPF schools and LA average Increase UCAS UCAS applicants as % of students entering for GCE exams 2011 62% 49% 64% 67% 69% This will applicant rate equate to an 59% additional Maintain stable conversion rates as KM Average 71% KM Av 65% 186 applicants (using same number of applicant volumes GCE exam increase entrants) Note: 2012 Actual is against a backdrop of falling applications for KM as a whole Increase UCAS accepted applicant rate UCAS accepted applicants as % of students entering for GCE exams 2011 41% KM Average 58% 43% 38% KM Av. 53% 45% 49% 52% This will equate to an additional 162 accepted applicants (using same number of GCE exam entrants)
Collaborative Targets. In collaboration with the University of Brighton, UCL will seek to:  Develop and deliver a joint initiative with primary schools in low progression neighbourhoods in London, with at least 85% considering higher education by the end of the programme.  Develop and deliver a package of IAG talks to schools and colleges in London, Kent and Sussex, working with five schools and 100 students a year.

Related to Collaborative Targets

  • Research Program The term “

  • Research Plan The Parties recognize that the Research Plan describes the collaborative research and development activities they will undertake and that interim research goals set forth in the Research Plan are good faith guidelines. Should events occur that require modification of these goals, then by mutual agreement the Parties can modify them through an amendment, according to Paragraph 13.6.

  • Collaboration 31.1 If the Buyer has specified in the Order Form that it requires the Supplier to enter into a Collaboration Agreement, the Supplier must give the Buyer an executed Collaboration Agreement before the Start date. 31.2 In addition to any obligations under the Collaboration Agreement, the Supplier must: 31.2.1 work proactively and in good faith with each of the Buyer’s contractors 31.2.2 co-operate and share information with the Buyer’s contractors to enable the efficient operation of the Buyer’s ICT services and G-Cloud Services

  • Development Milestones In addition to its obligations under Paragraph 7.1, LICENSEE specifically commits to achieving (either itself or through the acts of a SUBLICENSEE) the following development milestones in its diligence activities under this AGREEMENT: (a) (b).

  • Development Program A. Development activities to be undertaken (Please break activities into subunits with the date of completion of major milestones) B. Estimated total development time

  • Development Plan document specifying the work program, schedule, and relevant investments required for the Development and the Production of a Discovery or set of Discoveries of Oil and Gas in the Concession Area, including its abandonment.

  • Research Project The findings of any research project, which would change the provisions of this Agreement will not be implemented until such changes are negotiated and agreed to by the parties.

  • Research Collaboration 3.7.1 Aarvik shall carry out the activities of each Work Item and deliver the required Data Package and/or deliverables in accordance with the applicable SOW. Without limiting the generality of the foregoing, Aarvik shall, in accordance with the applicable SOWs and the timeline approved by JRC, apply the Aarvik IP to (i) design and synthesize Collaboration Compounds, and (ii) by itself or through subcontractor(s), [***]. During the Research Term, if any Party identifies any Third Party Patent or Know-How that is necessary or reasonably useful for any activity under the SOWs but has not been included in the Aarvik IP, then such Party shall immediately inform the other Party and the Parties shall discuss in good faith the need of obtaining a license from such Third Party. 3.7.2 No later than [***] ([***]) days after completion of the [***], Aarvik shall, to the extent not already provided to ArriVent, deliver the Data Packages and all other deliverables required under the [***], as well as the results of the Patentability and FTO Analysis as described in Section 3.2.3, to ArriVent. ArriVent shall have the sole discretion to decide whether or not to advance any Collaboration Compound and which Collaboration Compound(s) will be advanced for further studies beyond the [***]. ArriVent shall inform Axxxxx of its decision in writing. If AxxxXxxx decides to advance the Collaboration Program to [***], ArriVent shall make the payment for the [***] pursuant to Section 6.2.1. 3.7.3 If, upon completion of the [***] for the Collaboration Program, AxxxXxxx decides not to advance the Collaboration Program to [***], ArriVent may terminate the Collaboration Program. If AxxxXxxx decides to advance the Collaboration Program to [***], ArriVent shall make the payment for the [***] pursuant to Section 6.2.1. 3.7.4 No later than [***] ([***]) days after completion of the [***], Aarvik shall, to the extent not already provided to ArriVent, deliver all Data Packages and deliverables required under the [***] to ArriVent. ArriVent shall have the sole discretion to decide whether or not to advance any Collaboration Compound and which Collaboration Compound(s) will be advanced for further studies beyond the [***]. ArriVent shall inform Axxxxx of its decision in writing. 3.7.5 No later than [***] ([***]) days after completion of the [***], Aarvik shall, to the extent not already provided to ArriVent, deliver all Data Packages and deliverables required under the [***] to ArriVent. 3.7.6 Within [***] ([***]) days after completion of the [***], Aarvik shall deliver to ArriVent a full report on all key results and findings of the Collaboration Program, and such other data, results and information as ArriVent may deem necessary for it to determine whether or not to exercise the Option (the “Full Report”).

  • Development Milestone Payments Pfizer shall make the payments set forth below within [**] days (or [**] days after [**] following the first occurrence of each event described below for a Licensed Product Covered by a Valid Claim that achieves such milestone (each event a “Development Milestone” and each payment a “Development Milestone Payment”). Development Milestone Development Milestone Payment [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**]. The Development Milestone Payment in clause (2) of this Section 3.3 may become payable as set forth in Section 4.6. Whether or not the Development Milestone in clause (2) of this Section 3.3 is achieved, the Development Milestone Payment in clause (2) shall, pursuant to Section 4.6, in all cases become payable prior to the time the Development Milestone Payment in clause (3) of this Section 3.3 becomes payable. With respect to the Development Milestone in clause (3) of this Section 3.3, in the case of a [**] that is determined to have become [**], such Development Milestone, if achieved based on such [**], shall be achieved upon [**]; provided, however, if either [**], such Development Milestone shall be deemed to have been met on the date of such determination. With respect to the Development Milestone in clause (8) of this Section 3.3, such Development Milestone will be paid in [**], provided that if such Licensed Product [**]. (For the avoidance of doubt, all payment [**] that became payable prior to such [**] shall continue to be payable and there shall be [**] of the [**] Development Milestone Payment will be deemed to have been achieved and payable on [**], and will be paid by Pfizer within [**] days thereafter, until the earlier of [**]. For example, [**] of such Development Milestone, such Development Milestone Payment would be paid [**] of the Development Milestone [**]. For the avoidance of doubt: (a) except for (i) the Development Milestone Payment set forth in clause (6) of this Section 3.3 [**], (ii) the Development Milestone Payment set forth in clause (8) of this Section 3.3 [**] and (iii) the Development Milestone Payment set forth in clause (9) of this Section 3.3 [**], each Development Milestone Payment shall be payable only once upon achievement of the applicable Development Milestone and only on the first occurrence of the corresponding Development Milestone regardless of the number of Licensed Products and (b) satisfaction of a Development Milestone by an Affiliate or by a sublicensee or assignee of, or Third Party retained by, Pfizer or its Affiliates shall be deemed to have been satisfied by Pfizer for the purposes of this Section 3.3.

  • Research Term The term “